[Public Notices]PharmAbcine, non-confidential slide deck Q3 2021

27 Sep 2021
제목PharmAbcine, non-confidential slide deck Q3 2021

Notice of Changes:

  1. PharmAbcine received HREC (Human Research Ethics Committee) clearance to commence the Phase II combination trial of olinvacimab and pembrolizumab for the treatment of mTNBC (metastatic Triple-Negative Breast Cancer) in Australia
  2. 14 out of 36 patients have been recruited for the Phase IIa olinvacimab mono study for the treatment of Avastin refractory rGBM (recurrent Glioblastoma) in Australia and the U.S
  3. The competitive landscapes for the Company’s preclinical assets such as PMC-403 and PMC-309 have been updated

Thank you for your continued support.

Please check the attached file for details.

     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea

     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 

     COPYRIGHT BY PharmAbcine Inc.